Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label multicenter phase II study of SHR-A1811 injection in gynecologic malignancies
CTR20231632Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- Jul 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab rezetecan in Gynecological neoplasia, sponsored by Hengrui Therapeutics. Started Jul 2023; status: active.
02
Drugs
trastuzumab rezetecan
03
Conditions
Gynecological neoplasia
Beyond the preview
Go deeper on CTR20231632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231632.